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Summary
 
In the adaptive immune response to most viruses, both the cellular and humoral arms of the
immune system play complementary roles in eliminating virus and virus-infected cells and in
promoting recovery. To evaluate the relative contribution of CD4
 
1
 
 and CD8
 
1
 
 effector T lym-
phocytes in virus clearance and recovery, we have examined the host response to lethal type A
influenza virus infection in B lymphocyte–deficient mice with a targeted disruption in the im-
munoglobulin mu heavy chain. Our results indicate that naive B cell–deficient mice have a 50–
100-fold greater susceptibility to lethal type A influenza virus infection than do wild type mice.
However, after priming with sublethal doses of influenza, immune B cell–deficient animals
show an enhanced resistance to lethal virus infection. This finding indicates that an antibody-
independent immune-mediated antiviral mechanism accounts for the increased resistance to le-
thal virus challenge. To assess the contribution of influenza-specific CD4
 
1
 
 and CD8
 
1
 
 effector
T cells in this process, defined clonal populations of influenza-specific CD4
 
1
 
 and CD8
 
1
 
 effec-
tor T cells were adoptively transferred into lethally infected B cell–deficient mice. Cloned
CD8
 
1
 
 effectors efficiently promoted recovery from lethal infection, whereas cloned CD4
 
1
 
 T
cells conferred only partial protection. These results suggest that memory T lymphocytes can
act independently of a humoral immune response in order to confer resistance to influenza in-
fection in immune individuals. The potential implications of these results for vaccination
against human influenza infection are discussed.
 
F
 
or many viral infections, it has been suggested that the
cell-mediated immune response plays a dominant role
in recovery from disease, whereas the humoral, or B cell,
response is important for protection against free virus and
in preventing reinfection upon secondary exposure to an
identical or cross-reactive virus (1, 2). In the case of influ-
enza virus pneumonia, the disease can be cured either by a
CD8
 
1
 
 T cell response alone (3, 4), or, in the absence of
CD8
 
1
 
 T cells, by a CD4
 
1
 
 T cell and concomitant B cell
response (5, 6). In addition, studies examining the T cell–B
cell interactions occurring in response to influenza virus in-
fection have found that (
 
a
 
) adoptively transferred CD4
 
1
 
 T
cells can provide help for the production of neutralizing
anti-influenza virus antibody (7); (
 
b
 
) this antibody response
leads to virus clearance from the lungs of infected T cell–
deficient (nude) mice (7); and (
 
c
 
) transfer of neutralizing anti-
hemagglutinin (HA) antibody alone into infected SCID mice
(deficient in T and B cells) leads to influenza virus clearance
from the lungs of these immunodeficient mice (2, 8).
Since both activated CD4
 
1
 
 and, to a lesser extent, acti-
vated CD8
 
1
 
 T lymphocytes produce cytokines that can
augment B lymphocyte differentiation and the production
of neutralizing antibodies, the precise role of T cells in or-
chestrating recovery from experimental influenza infection
is not well defined. To assess the contribution of T lym-
phocyte effector activity, we have examined the response
of mice with a targeted mutation in the membrane exon of
the immunoglobulin 
 
m
 
 chain gene (B cell–deficient or 
 
m
 
knockout [KO] mice) to lethal primary and challenge type
A influenza virus infection and the effectiveness of trans-
ferred CD4
 
1
 
 and CD8
 
1
 
 T cells in virus clearance. We find
that while B cell–deficient mice are more susceptible to le-
thal influenza virus infection than are wild-type mice, ear-
lier vaccination of 
 
m
 
KO mice leads to enhanced resistance
to lethal influenza challenge. Also, CD8
 
1
 
 T cells are more
efficient than CD4
 
1
 
 T cells in promoting virus clearance
and recovery in the absence of B lymphocytes. Our results
indicate that the presence of influenza-specific memory
T lymphocytes in an immune individual results in increased
resistance to subsequent infection in the absence of neutral-
izing antibody.
 
Materials and Methods
 
Animals.
 
Pathogen-free male and female C57Bl/6 (H-2
 
b
 
)
mice were purchased from Taconic Farms, Inc. (Germantown, NY)
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and used at 6–12 wk of age. Breeding pairs of B cell–deficient
(H-2
 
b
 
) mice with a targeted mutation in the membrane exon of
the immunoglobulin 
 
m
 
 chain gene, or 
 
m
 
KO mice, provided by
K. Rajewsky (University of Cologne, Germany) (9), were bred
and maintained in a colony at the University of Virginia, and
were used at 6–12 wk of age.
 
Viruses.
 
Influenza virus strain A/JAPAN/57 (A/JAPAN/
305/57 [H2N2]) was grown in the allantoic cavity of 10-d-old
embryonated hens’ eggs and stored as infectious allantoic fluid as
previously described (10). Determination of virus titer, expressed
as hemagglutinating units, was done as previously described (10).
Influenza virus strain A/JAPAN/57 used for intranasal inocula-
tion and adoptive transfer procedures was mouse adapted by serial
passage in mouse lung and is lethal at concentrations as low as one
hemagglutinating units (equivalent to 10
 
4
 
 EID
 
50
 
, or egg infectious
dose, units). For procedures requiring a sublethal challenge of in-
fluenza, an egg-adapted, antigenically identical strain of A/JAPAN/
57 was used for intranasal inoculation. This preparation is not le-
thal for the mice used in these studies at concentrations equiva-
lent to 10
 
8
 
 EID
 
50
 
 units.
 
Intranasal Influenza Virus Inoculation.
 
Intranasal inoculation of
mice and determination of LD
 
50
 
 values was performed as previ-
ously described (11). To evaluate a dose response to intranasal vi-
rus, groups of 5–10 age-matched animals received serial 10-fold
dilutions of allantoic fluid in cold PBS ranging from 10
 
2
 
2
 
 to 10
 
2
 
6
 
and animals were watched daily for morbidity and/or mortality.
Each group consisted of both male and female mice as no differ-
ences have been observed when using age-matched mice.
 
Bulk and Clonal T Lymphocyte Lines.
 
Spleen cells from 
 
m
 
KO
and C57Bl/6 mice which had received a sublethal intranasal dose
of A/JAPAN/57 12 d before were harvested and processed as
previously described (11). Subsequently, these bulk cultures were
stimulated in vitro with influenza A/JAPAN/57 virus-infected,
gamma-irradiated (2,000 rad) C57Bl/6 spleen cells every 7–10 d
in complete medium (IMDM [GIBCO BRL, Gaithersburg, MD]),
10% HIFCS, 1% glutamine, 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME, and antibiotics)
with 15 U/ml human recombinant IL-2 (huRIL-2; Biosource
International, Inc., Camarillo, CA). The procedures developed to
establish and maintain the T cell clones used in these studies have
been described in detail elsewhere (11).
 
Assays for Cell-mediated Cytotoxicity.
 
The 
 
51
 
Cr-release cytotoxic-
ity assay and lysis calculations were carried out as previously de-
scribed in detail (10–12). Effector/target ratios ranged from 5:1 to
50:1 depending on assay. Spontaneous release was 
 
,
 
15%.
 
Adoptive Transfer Procedure.
 
Adoptive transfer of day 6 viable
cloned cells was performed as previously described (11, 12). 8–12-
wk-old C57Bl/6 and B cell–deficient mice were intranasally in-
oculated with 10 LD
 
50
 
 influenza A/JAPAN/57 virus, and within
30 min 10
 
7
 
 clone cells in 0.5 ml Iscove’s medium were injected
intravenously. Control mice were injected intravenously with 0.5
ml Iscove’s medium alone. Mice were watched daily for 21 d for
morbidity and/or mortality.
 
Results
 
To assess the impact of the presence or absence of B cells
on susceptibility to infection with influenza virus, cohorts
of age-matched C57Bl/6 and 
 
m
 
KO mice were inoculated
intranasally with varying doses of infectious mouse-adapted
A/JAPAN/57 influenza virus (10
 
2
 
3
 
–10
 
2
 
7
 
 dilutions of a stock
preparation with an infectious titer of 10
 
7
 
 EID
 
50
 
/ml in em-
bryonated eggs). As shown in Fig. 1, 
 
m
 
KO mice were
 
z
 
100-fold more susceptible to lethal virus infection than
were wild-type C57Bl/6 mice. The LD
 
50
 
 of this mouse-
adapted A/JAPAN/57 influenza virus was 10
 
3.8
 
 EID
 
50
 
 units
in wild-type C57Bl/6 mice and 10
 
1.7
 
 EID
 
50
 
 units in 
 
m
 
KO
mice, respectively. The titer of mouse-adapted virus used
for these studies was 
 
z
 
10
 
7
 
 EID
 
50
 
 units, which corresponds
to an LD
 
50
 
 of 10
 
3
 
 EID
 
50
 
 units in C57Bl/6 mice and an
LD
 
50
 
 of 10
 
1
 
–10
 
2
 
 EID
 
50
 
 units in 
 
m
 
KO mice.
It is well established that the host immune response to
primary influenza virus infection results both in a cell-
mediated immune response with the induction of CD8
 
1
 
CTLs and activated CD4
 
1
 
 T cells, and in a humoral response
with the production of neutralizing antibody (13–15). There-
fore, one likely explanation for increased susceptibility of
 
m
 
KO mice to influenza infection is the inability of 
 
m
 
KO mice
to mount a neutralizing antibody response. Indeed, 
 
m
 
KO
mice are unable to mount a serum influenza–specific anti-
body response after influenza infection (data not shown).
To determine if recovery from primary intranasal influ-
enza infection in 
 
m
 
KO mice correlated with the presence
of cellular immune effectors, e.g., CTLs, at the site of in-
fection, groups of 
 
m
 
KO and age-matched C57Bl/6 mice were
sublethally infected with the mouse-adapted A/JAPAN/57
virus. On day 12 after infection, the mice were killed, lungs
were excised, and mononuclear cells infiltrating the lungs
were collected and tested for in vitro cytolytic activity. As
Fig. 2 
 
a
 
 shows, mononuclear cells from the lungs of in-
fected 
 
m
 
KO mice and from conventional mice exhibited a
comparable degree of specific cytolytic activity on virus-
infected target cells in vitro. Similar results were obtained
when T cells were obtained at d 12 from lungs of wild-type
Figure 1. B cell–deficient mice are more susceptible to influenza viral
challenge. mKO (a) and C57Bl/6 (b) mice were intranasally inoculated
with varying doses (r, 1023 dilution; j, 1024 dilution; d, 1025 dilution;
m, 1026 dilution; and 6, 1027 dilution) of mouse adapted influenza virus
and watched for 21 d for morbidity and mortality. 
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and B cell–deficient mice recovering from nonlethal intra-
nasal infection with an attenuated A/JAPAN/57 virus
preparation (data not shown).
The finding of virus-specific cytolytic activity in the lungs
of 
 
m
 
KO mice recovering from sublethal primary infection
raised the possibility that primary infection would also result
in the development of virus-specific memory CD8
 
1
 
 (and
presumably CD4
 
1
 
) T lymphocytes capable of responding
to challenge infection with virus. To further examine this
hypothesis, two experimental approaches were employed.
First, immune splenocytes from 
 
m
 
KO and C57Bl/6 mice
were taken 28 d after priming by sublethal infection with
attenuated virus. These splenocytes were restimulated once
in vitro and subsequently tested for CTL activity. As shown
in Fig. 2 
 
b
 
, the in vitro secondary CTL response to A/JA-
PAN/57-infected stimulators between vaccinated 
 
m
 
KO and
C57Bl/6 mice was comparable. Second, groups of mKO and
wild-type mice were first vaccinated by intranasal infection
with a live attenuated (egg-adapted) A/JAPAN/57 virus
preparation. This attenuated virus stock has an LD50 for
mKO mice z1,000-fold higher than the challenge mouse-
adapted stock and is uniformly nonlethal for conventional
mice. It clears from the lungs of both conventional and B
cell–deficient mice by day 14 after infection (data not
shown). 28 d after vaccination, when CTL activity was no
longer detectable in the lungs of infected animals, the vac-
cinated mice were challenged by intranasal infection with
the aggressive mouse-adapted A/JAPAN/57 virus.
Fig. 3 shows the results of this priming/challenge study.
As expected, conventional mice, which have neutralizing
antiviral antibody both in the circulation and locally in the
respiratory tract, were uniformly resistant to lethal infection
with mouse-adapted virus at virus doses up to 106 EID50
units (i.e., the equivalent of an innoculum of 103 LD50
doses for a naive conventional mouse). By contrast, chal-
lenge infection of B lymphocyte–deficient mKO mice re-
sulted in death (Fig. 3). However, the immune mKO mice
demonstrated a 100-fold greater resistance to challenge in-
fection with mouse-adapted virus than did naive mKO mice
(LD50 values of 101.7 EID50 units and 104 EID50 units for
mouse-adapted virus in naive and vaccinated mKO mice,
respectively). These results suggest that the enhanced resis-
tance to lethal virus challenge observed in the primed B
cell–deficient mice was due to the activation of virus-spe-
cific memory T lymphocytes in response to challenge in-
fection.
In view of the evidence for both antibody independent
clearance of virus during primary infection of mKO mice
and enhanced resistance of these mice to lethal infection af-
ter priming, it was of interest to assess the contribution of
virus-specific CD41 and CD81 effector T lymphocytes to
recovery from infection in B cell–deficient mice. To exam-
ine this, we adoptively transferred clonal populations of
A/JAPAN/57 virus-specific CD41 and CD81 T lympho-
cytes into lethally infected conventional and mKO mice.
The clones used for these studies were H-2b haplotype-
restricted CD41 T cells (i.e., 4D7) and CD81 T cells (i.e.,
11E4 and B1.11), which have been previously character-
ized by us and have been shown to promote recovery
when adoptively transferred into lethally infected C57Bl/6
mice (11). Fig. 4 shows the survival data for one adoptive
transfer (representative of five independent experiments)
Figure 2. mKO mice can initiate and maintain an influenza-specific
CTL response after challenge with influenza virus. (a) Lungs were re-
moved from mKO (shaded bars) and C57BL/6 (open bars) mice on day 12
after intranasal viral challenge with a sublethal dose of A/JAPAN/57 (at-
tenuated strain). Cell suspensions from the lungs were obtained by pro-
cessing through a sieve, and were Ficoll purified and plated for a final ef-
fector/targer (E/T) ratio of 50:1. Assay time was 6 h and spontaneous
release for all targets was ,20%. Results of two separate experiments with
two mice per experimental group are shown. (b) Influenza specific bulks
from four individual mKO (shaded bars) and from C57BL/6 (open bars)
mice were tested for their ability to lyse uninfected and A/JAPAN/57 in-
fected class II negative (EL4) and class I and II positive (LB15.13) target
cells in a standard chromium release assay. Assay time 5 6 h; E/T 5 10:1.
Spontaneous release for all targets was ,15%. Experiment is representa-
tive of three separate experiments.
Figure 3. B cell–deficient mice are more susceptible to rechallenge
with influenza. Groups of 7–12 age-matched mKO (open symbols) and
C57Bl/6 (closed symbols) mice were intranasally infected with attenuated
A/JAPAN/57. 28 d later the animals were rechallenged intranasally with
the dilutions of mouse adapted A/JAPAN/57: n, 1021 dilution; s, 1022
dilution; e, 1023 dilution; h, 1024 dilution. Animals were followed for
21 d for mortality. Data is representative of two experiments.2066 Influenza Virus Clearance in B Lymphocyte–deficient Mice
carried out with these influenza-specific CD41 and CD81
T lymphocyte clonal effectors. As a control for each exper-
iment, the same number of influenza-specific CD41 or CD81
T cell clones were adoptively transferred into lethally chal-
lenged C57Bl/6 mice, and all three clones consistently pro-
moted 100% survival as previously published by this labora-
tory (11). The results of the adoptive transfers into C57Bl/6
mice are not shown as they are identical to those in our
previous publication (11), but results of the viral challenge
without concomitant clone transfer are shown in Fig. 4. In
addition to promoting recovery in C57Bl/6 mice, both
CD81 T cell clones efficiently promoted recovery in le-
thally infected mKO mice (Fig. 4). On the other hand, the
adoptively transferred clone of CD41 T cells conferred par-
tial protection in infected mKO mice with only 20% of the
clone recipients surviving lethal infection (Fig. 4). In four
other independent transfer experiments using these clonal
populations of CD41 and CD81 T cells, the overall sur-
vival for lethally infected mKO recipients of the virus-spe-
cific CD41 T cell clone ranged from 20 to 60%, whereas
the CD81 T cell clones reproducibly promoted recovery of
100% of infected mKO recipients.
This difference in the efficiency of virus clearance by
CD41 and CD81 immune effectors was not a unique prop-
erty of these three cloned T cell populations. In companion
experiments, bulk cultures of A/JAPAN/57 immune sple-
nocytes produced outcomes similar to their clonal counter-
parts upon adoptive transfer into lethally infected conven-
tional and B cell–deficient recipients. Fractionated bulk
populations of activated CD41 T cells promoted recovery
in 100% of conventional recipients and in only 40%–60%
of mKO recipients (data not shown). Like the virus-specific
CD81 clones (Fig. 4), bulk populations of CD81 CTL ef-
fectors were uniformly protective after adoptive transfer
into either conventional or B cell–deficient recipients.
Discussion
In this report we have examined recovery from lethal
pulmonary influenza infection in mKO mice. We found that
B lymphocyte–deficient mice show greater susceptibility to
lethal primary influenza infection than do conventional
mice with an intact B cell compartment. However, after
vaccination with attenuated virus, the mKO mice demon-
strate enhanced resistance to secondary challenge infection
with virulent virus. This finding is consistent with the pres-
ence of virus-specific memory T lymphocytes, which can re-
spond to and promote recovery from lethal challenge infec-
tion, in the vaccinated animals. Finally, we have observed
that virus-specific CD41 and CD81 effector T lympho-
cytes differ in their capacity to clear virus and to promote
recovery in infected B cell–deficient recipients.
The essential role of neutralizing antiviral antibody in
protection against reinfection has been well established for
influenza and most other viruses (2, 14, 16). The finding
that B lymphocyte–deficient mice demonstrate increased
sensitivity to lethal primary infection with type A influenza
suggests an important role for antiviral antibody in recovery
from primary influenza virus infection. Palladino et al. have
previously provided compelling evidence for a critical role
of neutralizing antibody in virus clearance during primary
influenza infection in the mouse (2). The findings reported
here support this concept. However, although no gross ab-
normalities in immune responsiveness have been reported
to date in mKO mice (9, 17, 18), more subtle alterations in
the host response to influenza in animals lacking mature
B2201 B cells (e.g., delayed T cell response kinetics) may
contribute to their increased susceptibility to lethal influ-
enza infection. It is noteworthy that Topham et al. recently
reported efficient clearing of influenza HKX-31 influenza
strain in mKO mice after sublethal infection (19). The find-
ings reported here are in agreement with those results; how-
ever, our results further suggest that although virus clear-
ance can be achieved in the absence of mature B cells, a
humoral immune response to the virus also makes an im-
portant contribution to the control of virus replication and
recovery from primary infection with a virulent virus strain.
A characteristic feature of influenza infection in the hu-
man is the susceptibility of immune individuals (primed by
earlier vaccination or natural infection) to infection with
serologically distinct variant virus strains of the same type A
influenza subtype as that which arises in the human popula-
tion through antigenic drift (20). Since these circulating vi-
ruses also share conserved antigenic epitopes recognizable by
human and murine CD41 and particularly CD81 T lym-
phocytes (13, 21) the contribution in immune individuals
of influenza-specific memory T lymphocytes directed to these
conserved antigenic epitopes in resistance to and recovery
from subsequent infection with drift variants has generally
been considered minimal (1). The results reported here sug-
gest otherwise. Earlier priming of B lymphocyte–deficient
mKO mice with a live attenuated virus resulted in a .100-
fold increase in the resistance of vaccinated mice to lethal
challenge infection. This finding implies that, like preexist-
Figure 4. CD81, but not CD41, T cell clones promote full recovery in
B cell–deficient mice. B cell–deficient (mKO) mice were infected intrana-
sally with a 10 LD50 dose of mouse-adapted A/JAPAN/57 virus followed
by an intravenous injection of 107 cells. The cells transferred included
4D7 (e, a CD41 clone), 11E4 (m, a CD81 clone), and B1.11 (d, a
CD81 clone). Mice receiving intranasal influenza, but no cell transfer, are
denoted as h. C57Bl/6 mice receiving intranasal influenza without cell
transfer are also shown (6). Each group represents 5–7 animals. Adoptive
transfer of these clones and media control into lethally challenged C57Bl/
6 mice was done simultaneously as a control.2067 Graham and Braciale Brief Definitive Report
ing neutralizing anti-influenza antibody, memory T lym-
phocytes present in influenza-immune individuals can act
to modify the course and severity of subsequent influenza
infections. In a recent report on the outcome of lympho-
cytic choriomeningitis virus (LCMV) infection in B lym-
phocyte–deficient mice, the presence of LCMV-specific
memory T cells induced by earlier vaccination likewise re-
sulted in enhanced resistance to challenge infection (22).
Our finding that the secondary CTL response elicited in
primed B cell–deficient mice is comparable to the CTL re-
sponse in immune animals with an intact B lymphocyte
compartment is in keeping with other recent reports in vi-
ral and nonviral models that demonstrated normal develop-
ment and maintenance of CD81 T cell memory in mice
lacking mature B lymphocytes (22, 23). However, as noted
above, T lymphocytes which differentiate in the absence of
B cells may develop compensatory mechanisms not normally
expressed by T lymphocytes developing and responding in
the presence of an intact B cell compartment. To assess the
relative contribution of CD41 and CD81 T cells to virus
clearance and recovery in mKO mice, we chose to adop-
tively transfer defined clonal and bulk populations of virus-
specific effector CD41 and CD81 T cells derived from B
cell–positive donors into lethally infected mKO recipients.
The results of this adoptive transfer analysis were clear
cut. Virus-specific CD81 T lymphocyte effectors were
equally effective at protecting from lethal infection and at
promoting recovery in both conventional and B lympho-
cyte–deficient recipients. On the other hand CD41 T lym-
phocyte effectors were as effective as CD81 T lymphocytes
in protecting mice with an intact B cell compartment, but
promoted recovery in only a fraction of lethally infected
mKO recipients. This result is in keeping with earlier ob-
servations of Scherle and co-workers that influenza-specific
CD41 T lymphocytes function in vivo to clear influenza
infection primarily by collaborating with B lymphocytes in
the production of antiviral antibody (7, 24).
However, it should be emphasized that we reproducibly
observed virus clearance and recovery in 20–60% of lethally
infected B lymphocyte–deficient mice after transfer of acti-
vated virus-specific CD41 T cells. Thus, one or more anti-
body-independent effector mechanisms appear to be used
by CD41 effector T cells to confer resistance to lethal chal-
lenge in some mKO recipients. Since the CD41 T cell clone
used in this study, 4D7, has been previously shown to ex-
press virus-specific MHC class II–restricted cytolytic activ-
ity in vitro (11) direct cytolysis of influenza-infected respi-
ratory epithelial cells would be the probable mechanism to
account for the antiviral effect of transferred CD41 T cell
effectors in mKO recipients. The recent studies of Tripp et
al. on virus clearance by CD41 T cells in influenza-infected
MHC class II–deficient mice provide compelling evidence
against direct cytolysis as a critical in vivo effector mecha-
nism of virus-specific effector CD41 T lymphocytes (25).
A more likely explanation for the antiviral effect of trans-
ferred CD41 T cells in mKO mice is that upon contact
with infected MHC class II–positive cells the CD41 effec-
tors release proinflammatory cytokines that could accelerate
the generation of specific CD81 T cell effectors in the in-
fected recipient and/or amplify nonadaptive innate im-
mune effectors mechanism with antiviral activity.
The ultimate goal of vaccination against viruses is to pre-
vent the establishment of infection and this can be most ef-
fectively achieved by the presence of preexisting neutraliz-
ing antibody at the initial site of infection. In the case of
type A influenza virus and other viruses that can undergo
extensive antigenic variation, vaccination to prevent infec-
tion is difficult to achieve. Therefore, it may be more real-
istic to also consider vaccination strategies that lessen the se-
verity of influenza infection. The results of the murine
influenza model reported here strongly suggest that, in an
immune individual, primed populations of influenza-speci-
fic memory T lymphocytes can act to modify the course and
severity of subsequent influenza infection. These findings
further imply that to be most effective a vaccine against hu-
man influenza should not only elicit a neutralizing antibody
response but should also efficiently prime virus-specific mem-
ory CD81 and CD41 T lymphocytes.
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